Novo Nordisk CFO on Wegovy, Tariffs, US Compounding
Novo Nordisk CFO Karsten Munk Knudsen speaks on Bloomberg Television about earnings, tariffs and the impact of compounding in the US, which he cites as a reason for the drugmaker's lower quarterly results and outlook cut. Speaking on Bloomberg Television, Knudsen says Novo is affected by compounding "significantly more" than its competitor Eli Lilly.
Terms and Privacy Policy